Related Experiment Video
Updated: May 21, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
Published on: June 4, 2012
[Antibiotherapy of infectious endocarditis].
Vanina Meyssonnier1, François Bricaire
1Groupe hospitalier de La Pitié-Salpêtrière, maladies infectieuses, VIH et tropicales, 75651 Paris Cedex 13.
Antibiotherapy is crucial for treating infectious endocarditis, requiring bactericidal drugs tailored to bacterial sensitivity. Treatment duration, particularly for prosthetic valve endocarditis, has been reduced with aminoglycoside combinations.
Area of Science:
- Infectious Diseases
- Cardiology
- Pharmacology
Context:
- Infectious endocarditis necessitates effective antibiotherapy.
- Prosthetic valve endocarditis often requires prolonged treatment durations.
- Bacterial sensitivity guides antimicrobial selection.
Purpose:
- To summarize current approaches in infectious endocarditis treatment.
- To highlight the role of bactericidal drugs and sensitivity testing.
- To discuss the impact of aminoglycoside combinations on treatment duration.
Summary:
- Antibiotherapy is the cornerstone of infectious endocarditis management.
- Treatment involves selecting bactericidal agents based on antibiogram results.
- Recent guidelines suggest shorter treatment courses, especially with aminoglycoside combinations, for prosthetic valve endocarditis.
Impact:
- Optimizing antibiotherapy regimens can improve patient outcomes.
- Shorter treatment durations may reduce drug toxicity and healthcare costs.
- Understanding drug sensitivity is key to successful infectious endocarditis management.
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis III: Medical Management
Mitral Stenosis III: Medical Management

